Exercising 'veto' power to make haploidentical hematopoietic stem cell transplantation a safe modality for induction of immune tolerance

Regenerative Medicine

Volumn 10, Issue 3, 2015, Pages 239-242

  Or Geva, Noga ^a   Reisner, Yair ^a  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

anti third party CD8 Tcm; kidney allograft acceptance; mixed chimerism; nonmyeloablative conditioning; reduced conditioning; T cell depletion; veto

Indexed keywords

CALCINEURIN INHIBITOR; CYCLOPHOSPHAMIDE; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; METHOTREXATE; MYCOPHENOLIC ACID; RAPAMYCIN; TACROLIMUS;

DRUG MEGADOSE; EDITORIAL; ENGRAFTMENT; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMATOLOGIC DISEASE; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; MORTALITY; NONHUMAN; NONMYELOABLATIVE CONDITIONING; OUTCOME ASSESSMENT; PATIENT SAFETY; PRIORITY JOURNAL; REDUCED INTENSITY CONDITIONING; STEM CELL MOBILIZATION; T CELL DEPLETION; WHOLE BODY RADIATION; ART; HEMATOPOIETIC STEM CELL; IMMUNOLOGY; TRANSPLANTATION TOLERANCE;

HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMATOPOIETIC STEM CELLS; HUMANS; PORTRAITS AS TOPIC; TRANSPLANTATION TOLERANCE;

EID: 84929990380     PISSN: 17460751     EISSN: 1746076X     Source Type: Journal    
DOI: 10.2217/rme.14.94     Document Type: Editorial

References (20)

1. Kanda Y, Oshima K, Asano-Mori Y et al. In vivo alemtuzumab enables haploidentical human leukocyte antigen-mismatched hematopoietic stem-cell transplantation without ex vivo graft manipulation. Transplantation 79(10), 1351-1357 (2005).
2. Luznik L, O'Donnell PV, Symons HJ et al. HLAhaploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and highdose, posttransplantation cyclophosphamide. Biol. Blood Marrow Transplant. 14(6), 641-650 (2008).
3. Raiola AM, Dominietto A, Ghiso A et al. Unmanipulated haploidentical bone marrow transplantation and posttransplantation cyclophosphamide for hematologic malignancies after myeloablative conditioning. Biol. Blood Marrow Transplant. 19(1), 117-122 (2013).
4. Kanakry CG, O'Donnell PV, Furlong T et al. Multiinstitutional study of post-Transplantation cyclophosphamide as single-Agent graft-versus-host disease prophylaxis after allogeneic bone marrow transplantation using myeloablative busulfan and fludarabine conditioning. J. Clin. Oncol. 32(31), 3497-3505 (2014).
5. Reisner Y, Kapoor N, Kirkpatrick D et al. Transplantation for severe combined immunodeficiency with HLAA, B, D, DR incompatible parental marrow cells fractionated by soybean agglutinin and sheep red blood cells. Blood 61(2), 341-348 (1983).
6. Kernan NA, Flomenberg N, Dupont B, O'Reilly RJ. Graft rejection in recipients of T-cell-depleted HLAnonidentical marrow transplants for leukemia. Identification of host-derived antidonor allocytotoxic T lymphocytes. Transplantation 43(6), 842-847 (1987).
7. Reisner Y. Engraftment of T-cell-depleted bone marrow in murine models for allogeneic bone marrow transplantation. Cancer Treat. Res. 50, 9-25 (1990).
8. Rachamim N, Gan J, Segall H et al. Tolerance induction by 'megadose' hematopoietic transplants: donor-Type human CD34 stem cells induce potent specific reduction of host anti-donor cytotoxic T lymphocyte precursors in mixed lymphocyte culture. Transplantation 65(10), 1386-1393 (1998).
9. Miller RG An Immunological Suppressor Cell Inactivating Cytotoxic T-lymphocyte Precursor Cells Recognizing It. Nature 287(5782), 544-546 (1980).
10. Aversa F, Tabilio A, Velardi A et al. Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype. N. Engl. J. Med. 339(17), 1186-1193 (1998).
11. Reisner Y, Hagin D, Martelli MF. Haploidentical hematopoietic transplantation: current status and future perspectives. Blood 118(23), 6006-6017 (2011).
12. Roy D, Lachance S, Kiss T et al. Haploidentical stem cell transplantation: high doses of alloreactive-T cell depleted donor lymphocytes administered post-Transplant decrease infections and improve survival without causing severe GvHD. Blood (ASH Annual Meeting Abstracts) 114, 512 (2009).
13. Di Ianni M, Falzetti F, Carotti A et al. Tregs prevent GvHD and promote immune reconstitution in HLA-haploidentical transplantation. Blood 117(14), 3921-3928 (2011).
14. Bachar-Lustig E, Rachamim N, Li HW, Lan F, Reisner Y. Megadose of T cell-depleted bone marrow overcomes MHC barriers in sublethally irradiated mice. Nat. Med. 1(12), 1268-1273 (1995).
15. Ophir E, Or-Geva N, Gurevich I et al. Murine antithird-party central-memory CD8(+) T cells promote hematopoietic chimerism under mild conditioning: lymphnode sequestration and deletion of anti-donor T cells. Blood 121(7), 1220-1228 (2013).
16. Reich-Zeliger S, Bachar-Lustig E, Bar-Ilan A, Reisner Y. Tolerance induction in presensitized bone marrow recipients by veto CTLs: Effective deletion of host anti-donor memory effector cells. J. Immunol. 179(10), 6389 (2007).
17. Kawai T, Sachs DH, Sprangers B et al. Long-Term results in recipients of combined HLA-mismatched kidney and bone marrow transplantation without maintenance immunosuppression. Am. J. Transplant. 14(7), 1599-1611 (2014).
18. Farris AB, Taheri D, Kawai T et al. Acute renal endothelial injury during marrow recovery in a cohort of combined kidney and bone marrow allografts. Am. J. Transplant. 11(7), 1464-1477 (2011).
19. Scandling JD, Busque S, Dejbakhsh-Jones S et al. Tolerance and withdrawal of immunosuppressive drugs in patients given kidney and hematopoietic cell transplants. Am. J. Transplant. 12(5), 1133-1145 (2012).
20. Leventhal J, Abecassis M, Miller J et al. Tolerance induction in HLA disparate living donor kidney transplantation by donor stem cell infusion: durable chimerism predicts outcome. Transplantation 95(1), 169-176 (2013).